Photo of William C. Rose

William C. Rose

Subscribe to William C. Rose's Posts

William Rose is an associate in the Litigation Department and a member of the Patent Law Group. His practice focuses on patent and related litigation and strategic counseling for life sciences and technology clients. He has extensive experience litigating in federal district courts, appellate proceedings, and inter partes review proceedings. William also has substantial experience advising life sciences clients on regulatory issues. William has advised clients and litigated issues involving both small molecule and biologic drugs (both on the patentee side and the generic/biosimilar side), medical devices, and developing technologies such as CRISPR and immunotherapy. William has also written extensively on patent and regulatory issues, and devotes time to training and mentoring new associates and summer associates on topics such as Hatch-Waxman and BPCIA litigation, as well as the regulatory framework governing such litigation.

In addition to serving corporate clients, William maintains an active pro bono practice, in which he twice received the Outstanding Achievement Award from the Washington Lawyers’ Committee for Civil Rights for obtaining highly favorable settlements on behalf of clients.

Prior to law school, William studied biomedical engineering at the University of Virginia, where he was selected as a Rodman Scholar (the honors engineering program) and worked in a laboratory researching targeted cancer treatment using ultrasound and nanotechnology, while also working as an emergency medical technician.

Contact: Read more about William C. Rose

In one of the first district court opinions applying the Federal Circuit’s recent GSK decision on induced infringement in the context of label carve-outs (the “GSK decision,” discussed here and here), Judge Richard Andrews in the District of Delaware held that plaintiff Amarin Pharma (“Amarin”) failed to plead facts sufficient to show that Hikma Pharmaceuticals’ (“Hikma”) carved-out product label and/or public marketing statements induced infringement of Amarin’s patents. The holding suggests that carved-out labels (so-called “skinny labels), despite the GSK decision, continue to provide some measure of protection from liability based on induced infringement.
Continue Reading Skinny Labels May Not Be Dead: Delaware District Court Distinguishes GSK, Dismisses Induced Infringement Claim

On August 5, 2021, the Federal Circuit withdrew its October 2020 opinion in GSK v. Teva, summarized in this post on induced infringement of method-of-treatment claims, and issued an opinion that reiterated the prior holding but sought to clarify its reasoning. GlaxoSmithKline v. Teva. Specifically, the majority stated that a generic manufacturer’s touting of AB equivalence to a brand drug is generally not evidence of intent to induce infringement—but in the specific facts of this case it did support inducement, because the Court found ample evidence tying claim limitations to statements in Teva’s label even though the patented method was omitted as a distinct indication. The Court also found that Teva’s advertising statements regarding treating “heart failure” evidenced intent to induce physicians to prescribe the drug to treat CHF.
Continue Reading GSK v. Teva: Federal Circuit Issues New Opinion Analyzing Induced Infringement

Reference product sponsors often obtain patents claiming methods of using a known drug to treat a condition or disease. Because generic and biosimilar developers typically do not treat patients, and thus do not directly infringe the claims, plaintiffs must sue under a theory of induced infringement—i.e., that the generic or biosimilar developer recommended, encouraged, or promoted a patented use for the drug. Demonstrating induced infringement most often involves the label of the defendant’s product, but increasingly may involve non-label evidence such as the defendant’s press releases, brochures, product catalogs, advertisements, and statements to the FDA, doctors, and investors. This non-label evidence is likely to be especially significant in the biologic context.
…
Continue Reading Induced Infringement of Method of Treatment Claims: Looking to the Label and Beyond